Reselute is a privately held medical device company advancing implant systems in orthopedics designed to integrate structural fixation with controlled local therapeutic delivery at the core of the implant.  

Our lead product, the Reselution™ Tibial Intramedullary Fixation System, is an investigational implant developed for high-risk fractures where infection remains a significant and persistent complication. The system combines load-bearing stabilization with sustained local antibiotic release within a single construct, embedding delivery directly within the implant architecture.

Through this approach, Reselute aims to advance precision implant technology in orthopedics, integrating controlled drug delivery with structural fixation to broaden how implants contribute to patient care beyond structural support alone. Our vision is to make drug-delivering implants a standard of care in orthopedic practice, starting with the tibia and expanding to other high-risk indications where infection remains a primary challenge.